Metastatic Gastric Cancer
Oncology·MeSH: Adenocarcinoma Of Esophagus
Prevalence
10.0 / 100K
Incidence
6.1 / 100K/yr
3 drugs in development·2 companies·4 clinical trials
Drug Pipeline by Phase
Approved(2)
Phase 3(1)
| Drug | Company |
|---|---|
| sugemalimab | EQRx, Inc. (EQRX) |
Compare drugs
Frequently asked questions
How many drugs are in development for Metastatic Gastric Cancer?
BioSniper tracks 3 drugs in development for Metastatic Gastric Cancer across 2 companies.
How many clinical trials target Metastatic Gastric Cancer?
There are 4 clinical trials targeting Metastatic Gastric Cancer tracked by BioSniper.
What is the prevalence of Metastatic Gastric Cancer?
The estimated prevalence of Metastatic Gastric Cancer is approximately 10.0 per 100,000 population.
Deep-dive into Metastatic Gastric Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis